Archives of Medical Research
Volume 41, Issue 1 , Pages 33-37 , January 2010

Expression of Syndecan-1 in Papillary Carcinoma of the Thyroid with Extracapsular Invasion

  • Ronell Bologna-Molina

      Affiliations

    • Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Jalisco, Mexico
    • Corresponding Author InformationAddress reprint requests to: R. Bologna-Molina, Paseo de las Galias 169, Colonia Lomas Estrella, CP 09890, México, D.F., México; Phone and fax: (+52) (55) 5695-2916
    • ,
  • Rogelio González-González

      Affiliations

    • Centro de Investigacion, Universidad de Cuautitlan Izcalli, Mexico
    • ,
  • Adalberto Mosqueda-Taylor

      Affiliations

    • Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico
    • ,
  • Nelly Molina-Frechero

      Affiliations

    • Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico
    • ,
  • Pablo Damián-Matsumura

      Affiliations

    • Departamento de Biología de la Reproducción, Universidad Autónoma Metropolitana Iztapalapa, Mexico City, Mexico
    • ,
  • Hugo Dominguez-Malagón

      Affiliations

    • Departamento de Patología Quirúrgica, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico

Received 23 June 2009 ,Accepted 23 October 2009.

References 

  1. Zou M, Al-Baradie RS, Al-Hindi H, et al. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer. 2005;93:1277–1284
  2. Cady B. Seminars in surgical oncology on thyroid cancer. J Surg Oncol. 2006;94:646–648
  3. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006;94:683–691
  4. Jukkola A, Bloigu R, Ebeling T, et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571–579
  5. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805–828
  6. Cross S, Wei JP, Kim S, et al. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer. J Surg Oncol. 2006;94:678–682
  7. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114:393–402
  8. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30:397–407
  9. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglylcan syndecan-1 mediates the fibroblast growth factor-2 binding and activity. J Cell Physiol. 1998;174:310–321
  10. Choi DS, Kim JH, Ryu HS, et al. Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer. 2007;121:741–750
  11. Anttonen A, Kajanti M, Heikkilä P, et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 1999;79:558–564
  12. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res. 2001;92:1062–1073
  13. Pulkkinen JO, Penttinen M, Jalkanen M, et al. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol. 1997;117:312–315
  14. Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer. 1997;74:482–491
  15. Anttonen A, Heikkilä P, Kajanti M, et al. High syndecan-1 expression is associated with favorable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer. 2001;32:297–305
  16. Fujiya M, Watari J, Ashida T, et al. Reduced expression of syndecan-1 affects metastasic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res. 2001;92:1074–1081
  17. Numa F, Hirabayashi K, Kawasaki K, et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int J Oncol. 2002;20:39–43
  18. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98:474–483
  19. Chen CL, Ou DL. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol. 2006;37:1279–1285
  20. Ito Y, Yoshida H, Nakano K, et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology. 2003;43:157–164
  21. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Geneva: WHO.
  22. Pan CC, Chen PC, Chiang H. An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morphol. 2004;12:370–372
  23. Götte M, Kersting C, Radke I, et al. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 2007;9:R8
  24. Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, et al. Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol. 2008;44:805–811
  25. Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003;55:20–29
  26. Harada K, Masuda S, Hirano M, et al. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 2003;34:857–863
  27. Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol. 2007;29:54–60
  28. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004;64:612–621
  29. Mennerich D, Vogel A, Klaman I, et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur J Cancer. 2004;40:1373–1382

PII: S0188-4409(09)00211-2

doi: 10.1016/j.arcmed.2009.11.004

Archives of Medical Research
Volume 41, Issue 1 , Pages 33-37 , January 2010

Article Tools

* Image Usage & Resolution